Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protein diaphanous homolog 2 (DIAPH2) is a member of the diaphanous subfamily of the formin homology proteins, which regulate the cytoskeleton, specifically actin filament elongation and microtubule stabilization[1][3][5]. DIAPH2 is expressed in various tissues, with noted roles in the development and function of the ovaries and emerging evidence for specialized expression and possible roles in cochlear hair cells and endosomal trafficking[1][3][5]. Genetic mutations or disruptions in DIAPH2 are linked to premature ovarian failure (POF), a disorder marked by ovarian dysfunction and early infertility, and may affect processes dependent on cytoskeletal remodeling such as cell division and motility[2][4][5]. DIAPH2 is also induced by Rho GTPases and interacts with proteins like RhoD to affect endosome motility[3][5]. At present, there are no known drugs that directly target DIAPH2, nor is it considered a standard pharmacotherapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Protein diaphanous homolog 2 (DIAPH2).